Merck’s Blockbuster Dreams for Osteoporosis Drug Delayed; Analysts Unfazed

Drug Industry Daily
A A
Merck is delaying by one year its plans to submit promising osteoporosis drug odanacatib for FDA approval so that a late-stage trial of the product can continue.

To View This Article:

Login

Subscribe To Drug Industry Daily